Related Experiment Video
Updated: Aug 23, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers
Sheena Pinto1, Jens Pahl1, Arndt Schottelius1
1Affimed GmbH, Heidelberg, Germany.
Abstract:
Bi-, tri- and multispecific antibodies have enabled the development of targeted cancer immunotherapies redirecting immune effector cells to eliminate malignantly transformed cells. These antibodies allow for simultaneous binding of surface antigens on malignant cells and activating receptors on innate immune cells, such as natural killer (NK) cells, macrophages, and neutrophils. Significant progress with such antibodies has been achieved, particularly in hematological malignancies. Nevertheless, several major challenges remain, including increasing their immunotherapeutic efficacy in a greater proportion of patients, particularly in those harboring solid tumors, and overcoming dose-limiting toxicities and immunogenicity. Here, we discuss novel antibody-engineering developments designed to maximize the potential of NK cells by NK cell engagers mediating antibody-dependent cellular cytotoxicity (ADCC), thereby expanding the armamentarium for cancer immunotherapy.
Insights
Multispecific antibodies enhance cancer immunotherapy by directing immune cells to target cancer cells. Novel antibody engineering aims to improve efficacy, especially for solid tumors, by maximizing natural killer (NK) cell potential.
Area of Science:
- Immunology and Cancer Therapy
- Antibody Engineering for Targeted Therapies
Background:
- Multispecific antibodies redirect immune effector cells (NK cells, macrophages, neutrophils) to eliminate cancer cells.
- Current successes are notable in hematological malignancies, but challenges persist for solid tumors.
- Limitations include increasing efficacy, overcoming dose-limiting toxicities, and managing immunogenicity.
Purpose of the Study:
- To discuss novel antibody-engineering strategies.
- To focus on maximizing the potential of natural killer (NK) cells in cancer immunotherapy.
- To expand therapeutic options using NK cell engagers.
Main Methods:
- Review of antibody-engineering developments.
- Focus on NK cell engagers.
- Exploration of antibody-dependent cellular cytotoxicity (ADCC) mechanisms.
Main Results:
- Novel engineering approaches are being developed.
- Strategies aim to enhance NK cell-mediated anti-tumor activity.
- Potential for improved therapeutic outcomes in cancer patients.
Conclusions:
- Advanced antibody engineering can overcome current immunotherapy limitations.
- Maximizing NK cell engagement is a promising strategy for broader cancer treatment.
- These developments expand the toolkit for effective cancer immunotherapy.
More Related Videos
Related Concept Videos
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Immune Surveillance by NK Cells and Phagocytes
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...

